Adc Therapeutics (NYSE: ADCT)
Adc Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Adc Therapeutics Company Info
ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.
News & Analysis
No articles found.
Valuation
Earnings Transcripts
ADC Therapeutics SA (ADCT) Q2 2022 Earnings Call Transcript
ADCT earnings call for the period ending June 30, 2022.
ADC Therapeutics SA (ADCT) Q1 2022 Earnings Call Transcript
ADCT earnings call for the period ending March 31, 2022.
ADC Therapeutics SA (ADCT) Q4 2021 Earnings Call Transcript
ADCT earnings call for the period ending December 31, 2021.
ADC Therapeutics SA (ADCT) Q3 2021 Earnings Call Transcript
ADCT earnings call for the period ending September 30, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.